JAKARTA. Syringe distributor company, PT Itama Ranoraya Tbk. (IRRA) recorded a fantastic performance in Q1-2021 compared to the same period in 2019 with net profit soaring 853.6% to IDR20.91 billion and revenue increasing 754.1% to IDR228.17 billion.
The high growth in the company's net profit was also followed by an increase in the company's profit margin. The company's operating profit margin in the first quarter of 2021 rose to 11.5 percent compared to the margin for the same period last year of 5.2 percent. Meanwhile, the net profit margin in the first quarter of 2021 rose to 9.2% from 8.3% in the first quarter of 2020.
President Director Itama Ranoraya Heru Firdausi Syarif revealed that the company's achievements in the first quarter of 2021 have met the target set. "In the first three months of this year we have realized 20% to 22% of the revenue target for 2021. We are optimistic that this year we can reach the target again," he said, Monday (19/4/2021). In 2021, IRRA targets 80%-100% growth for revenue and net profit.
In addition to swab antigen test products, blood plasma machines and ADS syringes products, IRRA will also sell new products, namely Avimac, an immunomodulator supplement for enhancing the body's immune system starting in the second quarter of 2021. Avimac initial production is targeted at 100,000-200,000 bottles.
Avimac is a high immunomodulator product from the Australian company 98 Alive which is led by Prof. Max Reynolds and is registered with TGA Australia and also has a distribution license from BPOM under the Avimac brand. The production process is carried out by PT Indofarma Tbk (INAF) which is also the owner of the distribution permit, for raw materials coming from PT Neumedik Indonesia (Affiliated Company), while IRRA becomes the Sole Distributor. (AM/LM)